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We read with interest the recent prospective observational study by Chan et al.[1] The authors 
aimed to investigate the inter- and intra-patient variability in dabigatran plasma levels with the 
110 and 150 mg bid dose regimens in 100 patients suffering from atrial fibrillation (AF). They also 
assessed the effect of physicians’ dose selection on plasma levels in the two different subgroups 
and explored whether a single trough measurement would identify patients with extreme plasma 
levels on subsequent visits, i.e. at 2-, 4- and 6-months [1]. They support the practice of selecting 
dabigatran dose based upon clinical characteristics because it results in similar levels of drug 
exposure in patients given the 110 or the 150 mg bid dose regimen. However, they do not support 
the concept that a single plasma level measurement with the Hemoclot Thrombin Inhibitor® 
(Hyphen BioMed) can be used to identify patients with consistently high or low plasma levels.  
 
In their study, Chan et al. revealed an impressive 17-fold variation in plasma concentrations (from 
≤ 30 ng/mL to 510 ng/mL) at trough (i.e. at a median of 13.3 ± 4.7 hours after the last drug 
intake) with an inter-patient geometric coefficient of variation (gCV) of 63.8%. This variation was 
equally important when plasma level was assessed at peak (i.e. at a median of 2.5 ± 0.2 hours 
after the drug intake) with an inter-patient gCV of 50.9%. They mention that the ranges of plasma 
levels were similar at baseline, 2-, 4- and 6-months. The greater variability observed at Ctrough is 
questionable as our study and another showed lower variability in samples taken at trough [2, 3]. 
The variability of the median delay since the last drug intake is more important for blood taken at 
trough (4.7 hours) than at peak (0.2 hours) which certainly explains an important part of this 
discrepancy. Consequently, this is a major limitation that prevents firm conclusions.  
 
Results of the intra-individual variability are even more equivoque. They founded gCVs of 32.9% 
and 39.5% for trough and peak levels, respectively. Based on the 100 patients screened at 
baseline, they defined the upper 20th centiles (n=20 patients) as equal to 129 ng/mL. Trough 
plasma levels remained above that threshold in 88.2%, 80.0% and 70.0% of patients at the 2-, 4- 
and 6-months visit, respectively. Similar analyses were performed for the upper 10th centiles 
(plasma level of 180 ng/mL and n=10 patients) as well as in the lower 20th centiles (plasma level 
of 38 ng/mL and n=20 patients). Based on these results, they mention that “over the 6 months 
measurement of drug concentrations, up to 40% of patients whose baseline trough level were in 
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the upper 20th and 10th centiles has subsequent levels that no longer fell within these respective 
extremes and that an even higher proportion (up to 80%) of patients with a single low trough 
measurement did not have subsequent level in the low extreme.” They conclude that “these 
findings highlight the limitation of a single Hemoclot® measurement in reliably identifying patients 
with extreme drug levels”. We believe that their conclusions should be interpreted more cautiously 
for the following reasons. First, the lack of individual data precludes firm conclusion regarding the 
concept of a single Hemoclot Thrombin Inhibitor® measurement. Namely, one cannot assert if it 
was the same patients that no longer fell within these respective extremes. In addition, from the 
20 patients identified upon the threshold of 129 ng/mL (the 20th centiles at baseline), data at 2-, 
4- and 6-months were only available for 17, 10 and 10 patients, respectively. That 50% of 
patients were not included at all stages of follow-up is clearly a limitation, as outlined by the 
authors [1]. More importantly, for trough plasma data, the median value of the delay since the last 
drug intake had an impressive variation of ± 4.7 hours. Thus, a patient initially identified above 
the threshold of 129 ng/ml can be normalized due to the fact that the delay since the last intake is 
more important at the 2-, 4- or 6-months visit. A previous simulated pharmacokinetic analysis 
from the RE-LY study stipulated that a 6-hour delay might put trough level outside the variability 
of a typical AF patient [2]. For the 20th lower centiles, the authors acknowledged that the test used 
has a limit of quantitation (LOQ) of 30 ng/mL. Our recent study demonstrated that for 
concentration ≤ 30 ng/mL it is certainly more appropriate to use a test dedicated to measure 
these low levels and probably not only < 30 ng/mL [3]. Moreover, other pre-analytical and 
analytical laboratory key information is still lacking and are not discussed here as a possible 
limitation. For example, there is no mention of the stability of dabigatran plasma sample at -80°C 
and its impact on the Hemoclot Thrombin Inhibitor® assay. If the analyses were performed within 
the same run, it is possible that the plasma collected 6 months, or more, before the experiment 
does not react similarly than a sample collected 2 months before the analysis. In addition, the 
authors failed to mention if different batches of the Hemoclot Thrombin Inhibitor® assay have been 
used and the delay between the blood sampling and the congelation is not stated.  
 
Furthermore, it would have been very interesting to obtain data on clinical outcomes as well as on 
the reason(s) for the 6 treatment cessations. However, and interestingly, Chan et al. found that 
dose adaptation based on the patients’ clinical characteristics (mainly age and renal clearance) 
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results in similar median trough and peak level. This confirms the choice of the different regulatory 
agencies to adopt the lower dose for patients with factors for drug accumulation [4-6]. 
 
In conclusion, the above limitations clearly highlight that the conclusions of Chan et al. probably 
need to be toned down. As previously mentioned, several criteria should be taken into 
consideration when considering proper drug monitoring: a high (A) intra- and (B) inter-individual 
variability in drug level, both justifying identification of the optimal dose for each patient at the 
start of treatment; (C) a low variability and good reproducibility in the assay method; (D) a 
correlation between drug level and clinical event and (E) the demonstration of the value of the 
therapeutic drug monitoring [7]. Up to now, the high intra- and inter-individual variability in drug 
level is clearly demonstrated [8] and the results from Chan et al. support this observation. 
Techniques for plasmatic drug measurements are evolving, suggesting that with appropriate 
methods, one can accurately assess the therapeutic response [3, 9-13]. The correlation between 
the drug level and the clinical event tends to be demonstrated [8], even if some criticisms have 
been raised [14], showing that further effort can also be made by assessing the plasma 
concentration at the time of the outcome. As mentioned above, delay since the last intake of the 
drug and the blood sampling is mandatory and strict protocols are needed to accurately 
investigate this. Therefore, a well-designed study, assessing the plasma level with adequate 
coagulation tests and restricting the delay since the last drug intake for the trough measurement 
at 12 hours ± max 1 hour, is still required to provide accurate recommendations on the usefulness 
of a single measurement to identify high or low responders. 
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